“The strategic and operational importance of having established and proved our own carbon nanotube and X-ray tube technology in-house cannot be overstated,” said Micro-X managing director Peter Rowland, in a statement. “We now have co-located, with our product manufacturing in Adelaide, complete control of the technology which will shape our destiny with our current and future products, as we develop and take to market the innovative X-ray products that only this technology can permit.”

The process has been locked down, with design verification completed, and meets the ISO 13485 standards and FDA requirements for supply of a Class II medical device. The company has created its own proprietary intellectual property around the new CNT emitter and method of manufacture, and filed a new patent that is in the process of being prosecuted.


Micro-X currently has a supply contract with XinRay for X-ray tubes for the DRX-Revolution Nano. The tubes are reported to be performing beyond expectations and will be ready to be fitted to DRX Revolution Nano deliveries for Carestream clients following reliability testing, which is expected to be completed in Q3 CY 2019 to ensure no disruption to the sales process with Carestream.

Manufacturing will take place adjacent to Micro-X’s current Tonsley facility.

Back to HCB News

Parts And Service Homepage